WIM INVESTMENT MANAGEMENT Ltd Raises Stake in GRAIL, Inc. $GRAL

WIM INVESTMENT MANAGEMENT Ltd boosted its holdings in GRAIL, Inc. (NASDAQ:GRAL) by 200.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 63,000 shares of the company’s stock after buying an additional 42,000 shares during the period. GRAIL makes up about 0.9% of WIM INVESTMENT MANAGEMENT Ltd’s investment portfolio, making the stock its 14th largest position. WIM INVESTMENT MANAGEMENT Ltd owned 0.17% of GRAIL worth $3,725,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in GRAL. Teacher Retirement System of Texas lifted its stake in shares of GRAIL by 5.5% during the second quarter. Teacher Retirement System of Texas now owns 8,538 shares of the company’s stock worth $439,000 after purchasing an additional 447 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of GRAIL by 28.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock valued at $76,000 after purchasing an additional 623 shares during the period. Profund Advisors LLC lifted its position in shares of GRAIL by 8.3% during the third quarter. Profund Advisors LLC now owns 9,442 shares of the company’s stock worth $558,000 after purchasing an additional 722 shares in the last quarter. NewEdge Advisors LLC boosted its stake in shares of GRAIL by 44.0% in the second quarter. NewEdge Advisors LLC now owns 2,535 shares of the company’s stock valued at $130,000 after purchasing an additional 775 shares during the period. Finally, Cypress Capital Management LLC WY grew its holdings in GRAIL by 64.3% during the 3rd quarter. Cypress Capital Management LLC WY now owns 2,300 shares of the company’s stock valued at $136,000 after purchasing an additional 900 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Canaccord Genuity Group cut their price objective on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Morgan Stanley decreased their price target on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a research report on Tuesday. Robert W. Baird set a $82.00 price target on shares of GRAIL in a report on Friday, February 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Finally, TD Cowen began coverage on shares of GRAIL in a report on Thursday, February 19th. They set a “hold” rating and a $114.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, GRAIL presently has an average rating of “Hold” and an average target price of $90.17.

GRAIL Stock Performance

Shares of NASDAQ:GRAL opened at $51.79 on Thursday. The company’s fifty day moving average is $94.24 and its two-hundred day moving average is $76.55. GRAIL, Inc. has a 1-year low of $20.44 and a 1-year high of $118.84. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -4.63 and a beta of 4.52.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. The business had revenue of $43.60 million during the quarter, compared to analyst estimates of $43.33 million. Sell-side analysts expect that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.